(Institución)
 
 

Docu-menta > Tecnología > Artículos de Tecnología >

Por favor, use este identificador para citar o enlazar este ítem: http://documenta.ciemat.es/handle/123456789/2305

Título : MT1-MMP as a PET imaging biomarker for cancer pancreas management.
Autor : Morcillo, Miguel Ángel
de Lucas, Ángel
Oteo, Marta
Romero, Eduardo
Magro, Natalia
Ibañez, Marta
Martínez, Alfonso
Garaulet, Guillermo
Arroyo, Alicia G.
López-Casas, Pedro Pablo
Hidalgo, Manuel
Mulero, Francisca
Martínez-Torrecuadrada, Jorge
Fecha de publicación : 1-feb-2024
Resumen : Pancreatic ductal adenocarcinoma (PDAC) continues to be one of the deadliest cancers for which optimal diagnostic tools are still greatly needed. Identification of PDAC-specific molecular markers would be extremely useful to improve disease diagnosis and follow-up. MT1-MMP has long been involved in pancreatic cancer, especially in tumour invasion and metastasis. In this study, we aim to ascertain the suitability of MT1-MMP as a biomarker for positron emission tomography (PET) imaging. Two probes were assessed and compared for this purpose, an MT1-MMP-specific binding peptide (MT1-AF7p) and a specific antibody (LEM2/15), labelled, respectively, with 68Ga and with 89Zr. PET imaging with both probes was conducted in patient-derived xenograft (PDX), subcutaneous and orthotopic, PDAC mouse models, and in a cancer cell line (CAPAN-2)-derived xenograft (CDX) model. Both radiolabelled tracers were successful in identifying, by means of PET imaging techniques, tumour tissues expressing MT1-MMP although they did so at different uptake levels. The 89Zr-DFO-LEM2/15 probe showed greater specific activity compared to the 68Ga-labelled peptide. The mean value of tumour uptake for the 89Zr-DFO-LEM2/15 probe (5.67 ± 1.11%ID/g, n=28) was 25-30 times higher than that of the 68Ga-DOTA-AF7p ones. Tumour/blood ratios (1.13 ± 0.51 and 1.44 ± 0.43 at 5 and 7 days of 89Zr-DFO-LEM2/15 after injection) were higher than those estimated for 68Ga-DOTA-AF7p probes (of approximately tumour/blood ratio = 0.5 at 90 min after injection). Our findings strongly point out that (i) the in vivo detection of MT1-MMP by PET imaging is a promising strategy for PDAC diagnosis and (ii) labelled LEM2/15 antibody is a better candidate than MT1-AF7p for PDAC detection.
URI : http://documenta.ciemat.es/handle/123456789/2305
ISSN : 1555-4309
Aparece en las colecciones: Artículos de Tecnología

Ficheros en este ítem:

Fichero Descripción Tamaño Formato
Miguel Ángel Morcillo_2018.pdf3.5 MBAdobe PDFVisualizar/Abrir
View Statistics

Los ítems de Docu-menta están protegidos por una Licencia Creative Commons, con derechos reservados.

 

Información y consultas: documenta@ciemat.es | Documento legal